Developer docs
API playgroundTry for free, no card

Search company profiles

Stemmatters SA

Full company profile

uuid000am2b

Namestring
Stemmatters SA
Legal namestring
Stemmatters, Biotecnologia e Medicina Regenerativa S.A.
Websiteurl
stemmatters.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Stemmatters SA is a privately held Portuguese biotechnology company founded in 2007 and headquartered at the Avepark Science and Technology Park in Guimarães, Portugal. It operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) focused on regenerative medicine, including cell therapies, advanced therapy medicinal products (ATMPs), blood-derived biologicals, and combination products built on its biomaterial platform. Its offering spans four service pillars: contract development, cGMP contract manufacturing, analytical services, and formulation development, supplemented by proprietary programs such as the TheraBoost biomaterial platform and the RHYTHMS iPSC process-control toolkit.

The company serves regenerative medicine developers, academic medical centers, and cell therapy companies through enterprise B2B engagements, with named partners including Pluristyx, Accelerated Biosciences, IPO Porto, and NOVA FCT. It holds GMP certification and EudraGMDP registration, is ISO 9001:2015 certified, and has integrated advanced instrumentation including the Agilent xCELLigence real-time cell analysis system and the Limula LimONE automated manufacturing platform. Stemmatters is also a leader or partner in multiple EU and Portuguese funded consortia (CAR T-REX, PAT4CGT, DCMatters, CAR T-Matters, RHYTHMS), which collectively have brought in over €11 million in non-dilutive funding between 2022 and 2025 and underpin its technology and capability build-out.

Commercially, Stemmatters generates revenue through project-based CDMO service contracts (development, manufacturing, analytical, and formulation work) with quote-based pricing that is not publicly disclosed. The company supplements commercial service revenue with substantial non-dilutive grant income, and pursues a horizontal segmentation strategy targeting regenerative medicine companies, academic medical centers, and cell therapy developers. Its go-to-market is primarily enterprise field sales supplemented by conference-driven lead generation at ISCT, BIO-EUROPE, and Advanced Therapies events, with thought leadership reinforced through scientific publications and consortium leadership.

Short descriptiontext

Stemmatters SA is a Portuguese cGMP-certified CDMO specializing in regenerative medicine, offering contract development, manufacturing, analytical, and formulation services for cell therapies, ATMPs, and biomaterial-based combination products to biotech and academic clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGuimarães, Portugal
HQ citystring
Guimarães
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy CDMO, regenerative medicine manufacturing, cGMP contract manufacturing, advanced therapy development, analytical services biopharma
Industry3 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development Services
TypeProfessional Services
Description

Process development and optimisation services for advanced therapy products, supporting clients from early development through clinical translation

stemmatters.com
2cGMP Manufacturing
TypeProfessional Services
Description

Manufacturing services for cell therapies, ATMPs, and biological products under current Good Manufacturing Practices

stemmatters.com
3Analytical Services
TypeProfessional Services
Description

Quality control testing and analytical method development for characterization of cell-based products

stemmatters.com
4Formulation Development
TypeProfessional Services
stemmatters.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1TheraBoost
Description

An engineered biomaterial platform developed to address critical challenges in the supply chain of cell and gene therapies (CGTs). The platform aims to improve manufacturing, transport, and scalability of advanced therapies through three innovations: Cell Engineering Platform, Cell Expansion Microcarriers, and Hypothermic Shipping Matrix.

stemmatters.com
Core offering1 text field

Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products, including cell therapies, advanced therapy medicinal products (ATMPs), and blood-derived biologicals. The company delivers end-to-end process development, cGMP contract manufacturing, analytical testing, and formulation development services to biotechnology and pharmaceutical clients. Operations span from material reception through fill-and-finish, batch release, storage, and retrieval under GMP-certified conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully treated 100+ patients with CAR T cell therapies through consortium partner IPO Porto
+2 more records
Product overview1 text field

Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products. Its core offering consists of four interconnected service pillars: Contract Development (process development and CMC support for cGMP translation), Contract Manufacturing (end-to-end cGMP production from material reception through fill-and-finish and batch release), Analytical Services (quality, safety, and regulatory compliance testing), and Formulation Development (biomaterial-enabled combination product development). These services are complemented by the Stemmatters Academy internal training program. The company also advances proprietary technology programs including TheraBoost (an engineered biomaterial platform for cell and gene therapy supply chain innovation) and the RHYTHMS project (advanced process control toolkit for iPSC manufacturing monitoring), targeting the advanced therapy community including human cell and tissue products, advanced cell therapies, and blood-derived biologicals.

Product and service4 records
1Contract Development Services
2Contract Manufacturing Services
3Analytical Services
4Formulation Development Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1RHYTHMS Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-20
Description

Eurostars-funded project with consortium partners Scinus, MyCellHub, and University Hospital Skåne. Project aims to develop advanced process control toolkit for real-time monitoring of iPSC expansion, enabling data-driven process control and scalable manufacturing protocols.

stemmatters.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-16
Description

Installation of LimONE device at Stemmatters facility - an all-in-one automated cell and gene therapy manufacturing platform. Partnership spanning over three years with Stemmatters contributing design inputs. Technology transfer part of PAT4CGT project for automated, non-invasive process monitoring.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-06
Description

Portuguese consortium led by Stemmatters in partnership with IPO Porto and NOVA FCT. Project aims to establish national capacity for CAR T cell therapy development and production in Portugal. Co-funded by COMPETE 2030 Programme. Stemmatters responsible for implementing CAR T manufacturing process with regulatory compliance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-16
Description

Strategic partnership to co-develop and co-market human iPSCs derived from human trophoblast stem cells (hTSC). Marks Accelerated Biosciences' entry into EU market. Partnership aims to establish capabilities to develop and manufacture hTSC-derived iPSC compliant with EU regulatory requirements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-22
Description

CAR T-REX International Consortium led by Stemmatters awarded €2.7M EIC Pathfinder Open Grant. Consortium includes TargetGene Biotechnologies (Israel), CiQUS (Spain), University of Debrecen (Hungary), and Leibniz-Institut für Immuntherapie (Germany). Project focuses on developing novel CAR T cells to prevent exhaustion in solid tumour treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-12
Description

Partnership to develop and manufacture iPSC-derived Mesenchymal Stem Cell (iMSC) banks. Stemmatters provides cGMP manufacturing capabilities while Pluristyx contributes iPSC technology and expertise. Collaboration enables large-scale, custom-designed iMSC production for non-clinical and clinical research projects.

7DCMatters Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-14
Description

€2.1M project combining dendritic cell vaccines with immune checkpoint inhibitors for solid tumour treatment. Consortium includes Stemmatters, IPO Porto, NOVA FCT, and CINTESIS. Stemmatters develops and manufactures third-generation dendritic cells with enhanced anti-tumour response capability.

stemmatters.com
8PAT4CGT Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-15
Description

PAT4CGT consortium awarded €4.7M EIC Pathfinder Grant for developing modular cell and gene therapy manufacturing platform. Consortium coordinated by Da Vinci Labs (France) with technical leader Limula (Switzerland), includes Jobst Technologies, TU Wien, Exothera, and Crowdhelix. Stemmatters provides end-user assessment and closed process validation.

stemmatters.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is the largest global CDMO with a dedicated Cell & Gene Technologies business offering process development, viral vector and cell therapy manufacturing. Comparable to Stemmatters as a cGMP cell therapy CDMO serving therapeutic developers, but at vastly greater scale, with multi-site global capacity and broader service offerings.

TypeBroad incumbent
Description

Catalent (now owned by Novo Holdings) is a major global CDMO with significant cell therapy capabilities, including autologous and allogeneic manufacturing and iPSC-related services. It competes with Stemmatters for clinical and commercial cell therapy manufacturing contracts but operates globally at a much larger scale.

TypeDirect peer
Description

AGC Biologics is a global CDMO offering cell and gene therapy development and manufacturing, including iPSC and cell therapy capabilities. Directly comparable to Stemmatters as a cGMP cell therapy CDMO with similar service pillars (process development, manufacturing, analytical), but with broader geographic footprint and larger capacity.

TypeBroad incumbent
Description

Charles River offers Cell & Gene Therapy CDMO services through its Manufacturing Solutions segment, including process development and cGMP manufacturing. Comparable to Stemmatters as a cell therapy manufacturing services provider, but operates at much larger scale with a broader preclinical-to-clinical portfolio.

TypeDirect peer
Description

RoslinCT is a Scotland-based CDMO focused on cell and gene therapy manufacturing, including iPSC-derived therapies and allogeneic cell banking. Directly comparable to Stemmatters as a specialist cell therapy CDMO serving regenerative medicine developers with cGMP manufacturing and process development capabilities.

TypeRegional player
Description

Cell and Gene Therapy Catapult operates a UK-based manufacturing center for cell and gene therapy developers, providing process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized cell therapy manufacturing hub with similar service offerings, primarily serving European developers.

TypeEmerging player
Description

Center for Breakthrough Medicines is a US-based cell, gene, and biological therapy CDMO offering process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized advanced therapy CDMO with end-to-end capabilities, but operating in the US market and at a different stage of growth.

8KBI Biopharma
TypeDirect peer
Description

KBI Biopharma is a CDMO offering cell line development, process development, and cGMP manufacturing for biologics and cell therapies. Comparable to Stemmatters as a specialized CDMO providing development and manufacturing services for advanced therapy developers, though KBI has broader biologics capabilities and a larger footprint.

9Exothera
TypeRegional player
Description

Exothera is a Belgium-based CDMO specializing in viral vectors and cell and gene therapy manufacturing, a PAT4CGT consortium partner of Stemmatters. Comparable as a European specialist CDMO in the cell and gene therapy space with similar scientific orientation and customer profile, though focused more on viral vector production.

TypeEmerging player
Description

Limula is a Swiss-based technology company developing automated cell and gene therapy manufacturing platforms (LimONE device) and a direct PAT4CGT consortium partner of Stemmatters. Adjacent rather than direct competitor — Limula provides automation technology that Stemmatters integrates into its CDMO services, making it a partner and potential ecosystem peer in the European CGT manufacturing value chain.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stemmatters SA

Biopharmaceutical CDMO Servicesstemmatters.com

Stemmatters SA is a Portuguese cGMP-certified CDMO specializing in regenerative medicine, offering contract development, manufacturing, analytical, and formulation services for cell therapies, ATMPs, and biomaterial-based combination products to biotech and academic clients.

What Stemmatters SA does

Stemmatters SA is a privately held Portuguese biotechnology company founded in 2007 and headquartered at the Avepark Science and Technology Park in Guimarães, Portugal. It operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) focused on regenerative medicine, including cell therapies, advanced therapy medicinal products (ATMPs), blood-derived biologicals, and combination products built on its biomaterial platform. Its offering spans four service pillars: contract development, cGMP contract manufacturing, analytical services, and formulation development, supplemented by proprietary programs such as the TheraBoost biomaterial platform and the RHYTHMS iPSC process-control toolkit.

The company serves regenerative medicine developers, academic medical centers, and cell therapy companies through enterprise B2B engagements, with named partners including Pluristyx, Accelerated Biosciences, IPO Porto, and NOVA FCT. It holds GMP certification and EudraGMDP registration, is ISO 9001:2015 certified, and has integrated advanced instrumentation including the Agilent xCELLigence real-time cell analysis system and the Limula LimONE automated manufacturing platform. Stemmatters is also a leader or partner in multiple EU and Portuguese funded consortia (CAR T-REX, PAT4CGT, DCMatters, CAR T-Matters, RHYTHMS), which collectively have brought in over €11 million in non-dilutive funding between 2022 and 2025 and underpin its technology and capability build-out.

Commercially, Stemmatters generates revenue through project-based CDMO service contracts (development, manufacturing, analytical, and formulation work) with quote-based pricing that is not publicly disclosed. The company supplements commercial service revenue with substantial non-dilutive grant income, and pursues a horizontal segmentation strategy targeting regenerative medicine companies, academic medical centers, and cell therapy developers. Its go-to-market is primarily enterprise field sales supplemented by conference-driven lead generation at ISCT, BIO-EUROPE, and Advanced Therapies events, with thought leadership reinforced through scientific publications and consortium leadership.

Stemmatters SA firmographics

Firmographics
Name
Stemmatters SA
Legal name
Stemmatters, Biotecnologia e Medicina Regenerativa S.A.
Website
https://stemmatters.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Stemmatters SA is a Portuguese cGMP-certified CDMO specializing in regenerative medicine, offering contract development, manufacturing, analytical, and formulation services for cell therapies, ATMPs, and biomaterial-based combination products to biotech and academic clients.
Ownership category
akta.pro rank

Stemmatters SA industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy CDMO
  • Regenerative medicine manufacturing
  • CGMP contract manufacturing
  • Advanced therapy development
  • Analytical services biopharma

Where Stemmatters SA is headquartered

Location

Headquarters

HQ city
Guimarães
HQ country
Portugal
HQ region
Europe

Offices1 record

Markets served

Stemmatters SA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Development Services: Process development and optimisation services for advanced therapy products, supporting clients from early development through clinical translation
  2. cGMP Manufacturing: Manufacturing services for cell therapies, ATMPs, and biological products under current Good Manufacturing Practices
  3. Analytical Services: Quality control testing and analytical method development for characterization of cell-based products
  4. Formulation Development:

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Stemmatters SA product offering

Product offering

Core offering

Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products, including cell therapies, advanced therapy medicinal products (ATMPs), and blood-derived biologicals. The company delivers end-to-end process development, cGMP contract manufacturing, analytical testing, and formulation development services to biotechnology and pharmaceutical clients. Operations span from material reception through fill-and-finish, batch release, storage, and retrieval under GMP-certified conditions.

Product overview

Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products. Its core offering consists of four interconnected service pillars: Contract Development (process development and CMC support for cGMP translation), Contract Manufacturing (end-to-end cGMP production from material reception through fill-and-finish and batch release), Analytical Services (quality, safety, and regulatory compliance testing), and Formulation Development (biomaterial-enabled combination product development). These services are complemented by the Stemmatters Academy internal training program. The company also advances proprietary technology programs including TheraBoost (an engineered biomaterial platform for cell and gene therapy supply chain innovation) and the RHYTHMS project (advanced process control toolkit for iPSC manufacturing monitoring), targeting the advanced therapy community including human cell and tissue products, advanced cell therapies, and blood-derived biologicals.

Differentiator

Problem solved

Functional benefit

Brands

  • TheraBoost: An engineered biomaterial platform developed to address critical challenges in the supply chain of cell and gene therapies (CGTs). The platform aims to improve manufacturing, transport, and scalability of advanced therapies through three innovations: Cell Engineering Platform, Cell Expansion Microcarriers, and Hypothermic Shipping Matrix.

Products and services

  • Contract Development Services
  • Contract Manufacturing Services
  • Analytical Services
  • Formulation Development Services

Quantifiable outcome

  • Successfully treated 100+ patients with CAR T cell therapies through consortium partner IPO Porto
  • +2 more outcomes

Companies that use Stemmatters SA

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Stemmatters SA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Stemmatters SA partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • RHYTHMS ConsortiumminorStrategic or Co-development Partner · 20 June 2025Eurostars-funded project with consortium partners Scinus, MyCellHub, and University Hospital Skåne. Project aims to develop advanced process control toolkit for real-time monitoring of iPSC expansion, enabling data-driven process control and scalable manufacturing protocols.
  • LimulacoreTechnology or Integration · 16 June 2025Installation of LimONE device at Stemmatters facility - an all-in-one automated cell and gene therapy manufacturing platform. Partnership spanning over three years with Stemmatters contributing design inputs. Technology transfer part of PAT4CGT project for automated, non-invasive process monitoring.
  • CAR T-Matters ConsortiumcoreStrategic or Co-development Partner · 6 June 2025Portuguese consortium led by Stemmatters in partnership with IPO Porto and NOVA FCT. Project aims to establish national capacity for CAR T cell therapy development and production in Portugal. Co-funded by COMPETE 2030 Programme. Stemmatters responsible for implementing CAR T manufacturing process with regulatory compliance.
  • Accelerated BiosciencescoreStrategic or Co-development Partner · 16 December 2024Strategic partnership to co-develop and co-market human iPSCs derived from human trophoblast stem cells (hTSC). Marks Accelerated Biosciences' entry into EU market. Partnership aims to establish capabilities to develop and manufacture hTSC-derived iPSC compliant with EU regulatory requirements.
  • CAR T-REX ConsortiumcoreStrategic or Co-development Partner · 22 June 2023CAR T-REX International Consortium led by Stemmatters awarded €2.7M EIC Pathfinder Open Grant. Consortium includes TargetGene Biotechnologies (Israel), CiQUS (Spain), University of Debrecen (Hungary), and Leibniz-Institut für Immuntherapie (Germany). Project focuses on developing novel CAR T cells to prevent exhaustion in solid tumour treatment.
  • PluristyxcoreStrategic or Co-development Partner · 12 May 2023Partnership to develop and manufacture iPSC-derived Mesenchymal Stem Cell (iMSC) banks. Stemmatters provides cGMP manufacturing capabilities while Pluristyx contributes iPSC technology and expertise. Collaboration enables large-scale, custom-designed iMSC production for non-clinical and clinical research projects.
  • DCMatters ConsortiumminorStrategic or Co-development Partner · 14 November 2022€2.1M project combining dendritic cell vaccines with immune checkpoint inhibitors for solid tumour treatment. Consortium includes Stemmatters, IPO Porto, NOVA FCT, and CINTESIS. Stemmatters develops and manufactures third-generation dendritic cells with enhanced anti-tumour response capability.
  • PAT4CGT ConsortiumcoreStrategic or Co-development Partner · 15 June 2022PAT4CGT consortium awarded €4.7M EIC Pathfinder Grant for developing modular cell and gene therapy manufacturing platform. Consortium coordinated by Da Vinci Labs (France) with technical leader Limula (Switzerland), includes Jobst Technologies, TU Wien, Exothera, and Crowdhelix. Stemmatters provides end-user assessment and closed process validation.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Stemmatters SA competitors and assessment

Company assessment

Broad incumbents

  • Lonza Cell & Gene Technologies: Lonza is the largest global CDMO with a dedicated Cell & Gene Technologies business offering process development, viral vector and cell therapy manufacturing. Comparable to Stemmatters as a cGMP cell therapy CDMO serving therapeutic developers, but at vastly greater scale, with multi-site global capacity and broader service offerings.
  • Catalent (Novo Holdings): Catalent (now owned by Novo Holdings) is a major global CDMO with significant cell therapy capabilities, including autologous and allogeneic manufacturing and iPSC-related services. It competes with Stemmatters for clinical and commercial cell therapy manufacturing contracts but operates globally at a much larger scale.
  • Charles River Laboratories: Charles River offers Cell & Gene Therapy CDMO services through its Manufacturing Solutions segment, including process development and cGMP manufacturing. Comparable to Stemmatters as a cell therapy manufacturing services provider, but operates at much larger scale with a broader preclinical-to-clinical portfolio.

Direct peers

  • AGC Biologics: AGC Biologics is a global CDMO offering cell and gene therapy development and manufacturing, including iPSC and cell therapy capabilities. Directly comparable to Stemmatters as a cGMP cell therapy CDMO with similar service pillars (process development, manufacturing, analytical), but with broader geographic footprint and larger capacity.
  • RoslinCT: RoslinCT is a Scotland-based CDMO focused on cell and gene therapy manufacturing, including iPSC-derived therapies and allogeneic cell banking. Directly comparable to Stemmatters as a specialist cell therapy CDMO serving regenerative medicine developers with cGMP manufacturing and process development capabilities.
  • KBI Biopharma: KBI Biopharma is a CDMO offering cell line development, process development, and cGMP manufacturing for biologics and cell therapies. Comparable to Stemmatters as a specialized CDMO providing development and manufacturing services for advanced therapy developers, though KBI has broader biologics capabilities and a larger footprint.

Regional players

  • Cell and Gene Therapy Catapult: Cell and Gene Therapy Catapult operates a UK-based manufacturing center for cell and gene therapy developers, providing process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized cell therapy manufacturing hub with similar service offerings, primarily serving European developers.
  • Exothera: Exothera is a Belgium-based CDMO specializing in viral vectors and cell and gene therapy manufacturing, a PAT4CGT consortium partner of Stemmatters. Comparable as a European specialist CDMO in the cell and gene therapy space with similar scientific orientation and customer profile, though focused more on viral vector production.

Emerging players

  • Center for Breakthrough Medicines: Center for Breakthrough Medicines is a US-based cell, gene, and biological therapy CDMO offering process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized advanced therapy CDMO with end-to-end capabilities, but operating in the US market and at a different stage of growth.
  • Limula: Limula is a Swiss-based technology company developing automated cell and gene therapy manufacturing platforms (LimONE device) and a direct PAT4CGT consortium partner of Stemmatters. Adjacent rather than direct competitor — Limula provides automation technology that Stemmatters integrates into its CDMO services, making it a partner and potential ecosystem peer in the European CGT manufacturing value chain.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Stemmatters SA social profiles

Digital presence

Stemmatters SA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stemmatters SA leadership team

Management profile

Number of profiles

Profiles3 records

Stemmatters SA funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stemmatters SA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stemmatters SA

What does Stemmatters SA do?

Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products, including cell therapies, advanced therapy medicinal products (ATMPs), and blood-derived biologicals. The company delivers end-to-end process development, cGMP contract manufacturing, analytical testing, and formulation development services to biotechnology and pharmaceutical clients. Operations span from material reception through fill-and-finish, batch release, storage, and retrieval under GMP-certified conditions.

Is Stemmatters SA a public or private company?

Stemmatters SA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Stemmatters SA founded?

Stemmatters SA was founded in 2007. It employs 11 to 50 people.

Where is Stemmatters SA based?

Stemmatters SA is headquartered in Guimarães, Portugal, in the Europe region.

How does Stemmatters SA make money?

Four revenue lines are on record. Contract Development Services are the primary driver. The others are cGMP Manufacturing, analytical Services and formulation Development.

Who are Stemmatters SA's main competitors?

Broad incumbents on record are Lonza Cell & Gene Technologies, Catalent (Novo Holdings) and Charles River Laboratories. Direct peers are AGC Biologics, RoslinCT and KBI Biopharma. Regional players are Cell and Gene Therapy Catapult and Exothera. Emerging players are Center for Breakthrough Medicines and Limula.

Does Stemmatters SA have an API?

No public API is recorded for Stemmatters SA.

What industry is Stemmatters SA in?

Stemmatters SA's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales